Postprandial Hyperglycemia
Conditions
Brief summary
Aim of the study is to investigate the effect of two different dosages of milk peptides on postprandial blood glucose profile in prediabetic subjects compared to placebo. This will be investigated in a cross-over double blind randomized placebo controlled study design. Additionally, long term effects on glucose status, insulin sensitivity and postprandial blood glucose profile will be investigated in a follow up 6-week open label phase with the low dose only.
Interventions
DIETARY_SUPPLEMENTLow dose milk peptide
what is the effect of milk peptides 1400mg on postprandial glycemia after a meal rich in carbohydrates (75g)
DIETARY_SUPPLEMENTHigh Dose milk peptide
what is the effect of milk peptides 2800mg on postprandial glycemia after a meal rich in carbohydrates (75g)
DIETARY_SUPPLEMENTPlacebo
what is the effect of placebo on postprandial glycemia after a meal rich in carbohydrates (75g)
Sponsors
Ingredia S.A.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
first phase of the study is RCT double blind placebo cross-over. The second phase is open during 6 weeks of supplementation
Intervention model description
double blind cross over and open for the phase II of the study
Eligibility
Sex/Gender
ALL
Age
30 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Male and female subjects with prediabetic HbA1c values between 5.7% - 6.4% and/or Fasting blood glucose ≥ 5.6 mmol/l (≥ 100 mg/dl) und \< 7.0 mmol/l (\< 125 mg/dl) (in venous plasma) * Age: 30-70 years * Body mass index 19-35 kg/m2 * Non-smoker * Caucasian * Availability and presence in the study unit for approx. 3.5 hours/ week for 3 times in a row with approx. 1 week of washout in between. * Signed informed consent form * No changes in food habits or physical activity 3 months prior to screening and during the study
Exclusion criteria
* Presence of disease or drug(s) influencing digestion and absorption of nutrients or bowel habits * Intake of medications known to affect glucose tolerance, e.g., diabetic medication, steroids, protease inhibitors or antipsychotics * Diagnosed Typ 2-Diabetics with medical treatment * Chronic intake of substances affecting blood coagulation (e.g. acetylic acid (100 mg as standard prophylactic treatment allowed when dose is stable 1 month prior to screening), anticoagulants, diuretics, thiazides (diuretics and thiazides allowed e.g. for hypertension treatment when dose is stable 1 month prior to screening)), which in the investigator's opinion would impact patient safety * Severe liver, renal or cardiac disease * Acute gastrointestinal diseases including diarrhea and/or vomiting within the last 2 weeks * Known inflammatory and malignant gastrointestinal diseases (i.e. colitis ulcerosa, Morbus Crohn, celiac disease, malignant diseases e.g. colon-cancer, rectum cancer, pancreatitis) * Clinically relevant findings as established by medical history, physical examination, clinical laboratory and/or vital signs * Major medical or surgical event requiring hospitalization within the previous 3 months * Intake of antibiotics within 4 weeks before the test days * Known alcohol abuse or drug abuse * Pregnant or breast feeding women * Known or suspected allergy to any component of the investigational product(s) (e.g. milk protein) * Known HIV-infection * Known acute or chronic hepatitis B and C infection * Blood donation within 4 weeks prior to visit 1 or during the study * Subject unable to co-operate adequately * Participation in a clinical study with an investigational product within one month before start of study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Glucose-iAUC(0-180min) | day 1, day 8, day 15, day 57 | Area under the curve calculated as the incremental area under the blood glucose response curve, ignoring the area beneath the fasting concentration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Max-Increase | day 1, day 8, day 15, day 57 | Cmax minus baseline value |
| Tmax | day 1, day 8, day 15, day 57 | Time to reach maximum blood glucose concentration |
| Tbaseline | day 1, day 8, day 15, day 57 | First time to reach baseline again after increase or decrease in blood glucose |
| AUC(0-180min): | day 1, day 8, day 15, day 57 | Total area under curve from 0 to 180 min for blood glucose concentration |
| Insulin-iAUC(0-180min) | day 1, day 8, day 15, day 57 | Area under the curve calculated as the incremental area under the Insulin response curve, ignoring the area beneath the fasting concentration |
| Cmax Baseline Insulin Max_increase Insulin | day 1, day 8, day 15, day 57 | Max\_increase Insulin Cmax minus baseline insulin value |
| Cmax | day 1, day 8, day 15, day 57 | Maximum blood glucose concentration |
| Fasting glucose, fasting insulin | Baseline and Day 57 | — |
| HOMA index | Baseline and Day 57 | Parameters of insulin sensitivity: |
| HbA1c level | Baseline (V5) and Day 57 (after 6 weeks) | HbA1c level after 6 weeks of supplementation |
| Matsuda index | Baseline and Day 57 | Insulin sensitivity |
| Quicki Index | Baseline and Day 57 | Insulin sensitivity |
| Tmax insulin | day 1, day 8, day 15, day 57 | time to reach maximum Insulin concentration |
Countries
Germany
Outcome results
None listed